VA National Formulary Act of 2025
Summary
HR6580 (VA National Formulary Act of 2025) is a procedural bill to codify and standardize the VA's national drug formulary, restricting local formularies. Currently in committee with no cosponsors and no funding authorization, it poses minimal near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6580 is a procedural bill with no authorized funding or direct market impact.
- 2.It standardizes VA formulary management but does not change drug coverage or procurement.
- 3.No cosponsors and a junior sponsor indicate low legislative momentum.
Market Implications
No meaningful market implications. The bill does not affect drug pricing, reimbursement, or procurement. Investors should monitor for future amendments or a companion bill that could introduce financial mechanisms, but currently this is a non-event.
Full Analysis
The VA National Formulary Act of 2025 (HR6580) was introduced by Rep. Miller-Meeks (R-IA) on December 10, 2025, and referred to the House Committee on Veterans' Affairs. The bill amends title 38 to formally establish a national formulary managed by the VA's Pharmacy Benefits Management Service, prohibiting local Veterans Integrated Service Networks or medical centers from maintaining separate formularies unless specific waivers are granted. Two committee hearings were held (March and May 2026), but the bill remains at the hearing/markup stage. It has no cosponsors, and the sponsor is a junior member (first elected in 2020). No funding authorization is included; the bill is purely structural and administrative. Because it does not alter drug coverage, pricing, or procurement mechanisms, it does not directly affect any publicly traded company's revenue or competitive position. The legislative path forward requires full committee markup, floor passage in the House, Senate consideration, and presidential action—a timeline that could extend beyond the 119th Congress. Convergence signals were not provided; this bill stands alone as a low-impact procedural measure.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DEPARTMENT OF HUMAN SERVICES HAWAII: $2.2B Department of Health and Human Services Grant
KANSAS DEPARTMENT OF HEALTH & ENVIRONMENT: $4.6B Department of Health and Human Services Grant
NEW MEXICO HEALTH CARE AUTHORITY: $9.4B Department of Health and Human Services Grant
HEALTH SERVICES KENTUCKY CABINET FOR: $18.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.1B Department of Health and Human Services Federal Award
ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM: $19.6B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
HEALTH CARE SERVICES, CALIFORNIA DEPARTMENT OF: $6.2B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →